Search clinical trials for: RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B

Total 49 results

GlaxoSmithKline

Completed

A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults

Respiratory Syncytial Virus Infections

United States, Belgium
GlaxoSmithKline

Completed

A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults

Respiratory Syncytial Virus Infections

Japan
Novavax
PATH

Completed

RSV-F Vaccine Dose Ranging Study in Young Women

Respiratory Syncytial Virus (RSV)

United States
GlaxoSmithKline

Completed

Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population

Influenza

Belgium
Vaxart

Completed

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

Respiratory Syncytial Virus (RSV)

United States
GlaxoSmithKline

Completed

A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants

Respiratory Syncytial Virus Infections

Taiwan, Spain, United States, Italy, Canada, Panama, Mexico, Poland
Novavax

Completed

RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly

Respiratory Syncytial Virus (RSV)

United States
Medigen Vaccine Biologics Corp.

Completed

A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects

H7N9 Influenza Vaccine

Taiwan
Vaxxas Pty Ltd
Biomedical Advanced Research and Development Authority

Not yet recruiting

Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (HD-MAP)

H7N9 Influenza

Australia
GlaxoSmithKline
Biological E. Limited

Recruiting

Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults

Typhoid Fever

Belgium
Curevo Inc
Green Cross Corporation; Mogam Biotechnology Research Institute

Active, not recruiting

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

Herpes Zoster | Shingles

United States
Blue Lake Biotechnology Inc.

Recruiting

A Study of BLB-201 RSV Vaccine in Infants and Children

Respiratory Syncytial Virus Infections

United States
GlaxoSmithKline

Terminated

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

Herpes Simplex

United States
Medicago

Completed

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

Canada
Merck Sharp & Dohme LLC

Completed

Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)

Dengue
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico) (DPIV-002)

Dengue Fever

Puerto Rico
Novavax

Completed

RSV F Dose-Ranging Study in Women

Respiratory Syncytial Virus Infections

United States
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Shanghai Public Health Clinical Center; Beijing Simoonrecord Pharmaceutical...

Completed

A Phase ⅠStudy of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)

Tuberculosis

China
Novavax

Completed

A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age

Respiratory Synctial Virus

Canada
Pauline Verdijk
World Health Organization

Completed

Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants

Poliomyelitis

Poland
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years

Clostridium Infections

Belgium
Novavax

Completed

Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults

Respiratory Syncytial Viruses

Australia
Novavax
Bill and Melinda Gates Foundation

Completed

A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization

Respiratory Syncytial Virus Infections

United States, Argentina, Australia, Bangladesh, Chile, Mexico, New Zealand, Philippines, South Africa, Spain, United Kingdom
Duke University
Johns Hopkins University; Centers for Disease Control and Prevention

Completed

Simultaneous RZV and aIIV4 Vaccination

Quality of Life | Pain | Adverse Drug Event | Injection Site Reaction

United States
Novartis Vaccines

Completed

Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years

H7N9 Influenza

United States
U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR); Naval Medical Research Center; Vic...

Completed

Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease (TVDV)

Dengue Fever | Dengue Disease

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults

Diarrhea | Clostridium Difficile Infection

United States
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate

Influenza

Belgium
Novavax

Completed

RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.

Respiratory Syncytial Virus Infections

United States
MAXVAX Biotechnology Limited Liability Company
Henan Center for Disease Control and Prevention

Active, not recruiting

Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above

Herpes Zoster

China
Novavax

Completed

Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine

Covid19 | SARS-CoV Infection

Australia
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.

Malaria | Malaria Vaccines

Ghana
Beijing Chaoyang District Centre for Disease Control...

Completed

Safety and Immunogenicity Study of Live Attenuated Vaccine Against Herpes Zoster in Chinese Adults Aged 50 Years and Older

Herpes Zoster
Medicago
McGill University Health Centre/Research Institute of the McGill University... and other collaborators

Completed

Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

Canada
Novavax

Active, not recruiting

A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. (COVID-19)

COVID-19

United States
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

A Phase Ib Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)

Tuberculosis

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Suspended

A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)

Tuberculosis

China
Medicago
Health Sciences Centre, Winnipeg, Manitoba; Syneos Health; Public Health Agency...

Completed

Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

Canada
GlaxoSmithKline

Completed

Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine

Respiratory Disorders

France, Estonia, Spain, Finland, Italy
Novavax

Completed

A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19) (COVID-19)

SARS-CoV-2 Infection

South Africa
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Withdrawn

TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant

Dengue

United States
Sanofi Pasteur, a Sanofi Company
GlaxoSmithKline

Completed

Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older

COVID-19 (Healthy Volunteers)

United States
Novavax

Not yet recruiting

A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

COVID-19
Korea University Guro Hospital
Korean Center for Disease Control and Prevention

Active, not recruiting

Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)

COVID-19 (Healthy Volunteers)

Korea, Republic of
Centre Hospitalier Universitaire Vaudois

Recruiting

Personalized DC Vaccines in Non Small Cell Lung Cancer

Non-small Cell Lung Cancer

Switzerland
Ology Bioservices

Completed

Safety and Immunogenicity Study of a Ross River Virus (RRV) Vaccine

Ross River Virus Disease (RRVD)

Netherlands, Austria, Belgium
Peking Union Medical College Hospital

Recruiting

Dexmedetomidine and Sufentanil Effect in PCA on Pediatric Patients Undergoing Scoliosis Surgery (DEX)

Dexmedetomidine

China
Jianxiang Wang

Unknown

Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old

Acute Myeloid Leukemia

China
Joseph Baar, MD, PhD

Completed

MUC1 Vaccine for Triple-negative Breast Cancer

Breast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer

United States

3

Subscribe